Trials / Recruiting
RecruitingNCT06199037
Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Intravenous Administration of SHR-1707 In Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 45 (estimated)
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 50 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate the Safety, Tolerability and Pharmacodynamics of Intravenous Administration of SHR-1707 In Patients with Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1707 | 1 cohort of Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease patients will receive SHR-1707 injection |
| DRUG | SHR-1707 placebo | 1 cohort of Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease patients will receive SHR-1707 placebo injection |
Timeline
- Start date
- 2024-02-05
- Primary completion
- 2025-04-30
- Completion
- 2026-06-24
- First posted
- 2024-01-10
- Last updated
- 2024-04-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06199037. Inclusion in this directory is not an endorsement.